State Street Corp Fate Therapeutics Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Fate Therapeutics Inc stock. As of the latest transaction made, State Street Corp holds 5,252,974 shares of FATE stock, worth $8.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,252,974

Previous 5,338,689 1.61%

Holding current value

$8.46 Million

Previous $17.5 Million 5.0%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.12 - $5.57 $267,430 - $477,432	-85,715 Reduced 1.61%	5,252,974 $18.4 Million
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $8.8 Million - $19.1 Million	-2,697,980 Reduced 33.57%	5,338,689 $17.5 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $21.9 Million - $51.6 Million	6,174,750 Added 331.63%	8,036,669 $59 Million
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $676,509 - $1.62 Million	-410,006 Reduced 18.05%	1,861,919 $6.96 Million
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $16.2 Million - $40.5 Million	-8,041,986 Reduced 77.97%	2,271,925 $4.82 Million
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $21.5 Million - $29.8 Million	-4,516,173 Reduced 30.45%	10,313,911 $49.1 Million
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $37.7 Million - $98.9 Million	8,894,625 Added 149.86%	14,830,084 $84.5 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $15.3 Million - $37 Million	1,552,825 Added 35.43%	5,935,459 $59.9 Million
Q3 2022 Nov 15, 2022	SELL	$21.04 - $36.06 $18.7 Million - $32 Million	-887,501 Reduced 16.84%	4,382,634 $98.2 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $32 Million - $76.2 Million	1,797,703 Added 51.77%	5,270,135 $131 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $22.4 Million - $45.4 Million	753,639 Added 27.72%	3,472,432 $135 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $16.1 Million - $21.7 Million	337,254 Added 14.16%	2,718,793 $159 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $19.4 Million - $31.3 Million	326,993 Added 15.92%	2,381,539 $141 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $4.8 Million - $6.6 Million	71,350 Added 3.6%	2,054,546 $178 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $8.96 Million - $14.6 Million	-124,177 Reduced 5.89%	1,983,196 $164 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $30.3 Million - $80.2 Million	-794,735 Reduced 27.38%	2,107,373 $192 Million
Q3 2020 Nov 10, 2020	SELL	$30.41 - $40.5 $6.07 Million - $8.08 Million	-199,533 Reduced 6.43%	2,902,108 $116 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $12.9 Million - $22.4 Million	636,102 Added 25.8%	3,101,641 $106 Million
Q1 2020 May 11, 2020	BUY	$17.28 - $31.88 $42.6 Million - $78.6 Million	2,465,539 New	2,465,539 $54.8 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $156M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Fate Therapeutics Inc Transaction History